Pricing Log in Create free account
Saturday 7 November 2026 Export DTIL’s income statement to Excel — free account

Precision BioSciences, Inc.

DTIL Healthcare Biotechnology

Precision BioSciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $34.3 million, down 50.1% from fiscal 2024.

Revenue
+37,272.4%
EPS
+85.0%
Free cash flow
−0.52%
Total debt
+0.22%

Quarter to September 2026, against a year earlier

10.75 0.88 +8.92%
Market cap
$275.7M
P/E
0.0×
Fwd P/E
−2.9×
Dividend yield
—
F-score
1/9
Altman Z
−4.31
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 0.06
Sold, $m 0.43
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 3 — — — — — — — — 3 — —
Sell — 4 4 — — — — — — — — —
Insider Ownership 12.95%

Capital & Financial Ratios $m

Size
Market Cap 275.73
Revenue ttm 45.07
Net income ttm (38.55)
Free cash flow ttm (52.40)
Net debt Q (59.42)
Valuation
P/E 0.00
Forward P/E (2.93) (negative: loss-making)
Price / sales 6.54
Forward P/S Powerpack
Price / FCF 0.00
Price / book 5.70
Financial health
Current ratio Q 10.47 (at or above 1.5: strong)
Debt / equity Q 0.43 (at or below 0.5: strong)
Interest coverage Q (66.54)
Growth
Revenue growth Q +37,272.41% (above 0%: growing)
Operating income growth Q +1.16% (above 0%: growing)
EPS, this year +14.89%
EPS, next year A +15.38% (at or above 15%: strong)
Revenue, next year A −60.66% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +20.67% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 5.2×, against a ten-year median of 2.2×; over the ten years it ranged from −2.8× in 2022 to 106× in 2025.
P/S against its own 10 years 59.69%
10-year low 10-year high
P/B against its own 10 years 83.34%
10-year low 10-year high
EV/Sales against its own 10 years 34.61%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 117 86 116 82
Receivables 1 0 — —
Inventory — — — —
Other 1 2 0 0
136 95 119 87
2023 2024 2025 Q'26
Payables 3 1 0 1
ST’ Debt — — — —
Other 2 1 1 1
50 15 9 8

Compound Annual Growth %

10y 5y 3y
Sales — 7.13% 10.93%
Cash Flow — 0.00% 0.00%
Earnings — 0.00% 0.00%
Book Value — 15.74% 15.14%

Earnings Trends EPS, adjusted, against the consensus

Q3 FY26 Estimate −1.02 Actual −0.65

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q4 FY25 −0.21 0.36 Beat by 0.57
Q1 FY26 −0.27 −0.34 Miss by 0.07
Q2 FY26 −0.74 −0.71 Beat by 0.03
Q3 FY26 −1.02 −0.65 Beat by 0.37
Q4 FY26 −0.99 — Reports 11 March 2027

EPS $

Mar Jun Sep Dec Year
’26 (0.75) (1.26) (0.28) — —
’25 (2.21) (2.13) (1.84) 1.05 (3.56)
’24 1.70 4.67 (2.25) (2.22) 1.04
’23 (6.91) (3.00) (2.10) (4.06) (15.96)
’22 (13.81) (13.81) (6.61) (7.81) (38.14)
’21 (9.91) 10.81 (5.71) (11.41) (15.62)
’20 (15.62) (18.92) (15.01) (13.21) (62.76)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 11 — — — —
’25 0 0 0 34 34
’24 18 50 1 1 69
’23 9 20 13 7 49
’22 3 4 7 11 25
’21 16 69 24 6 116
’20 7 1 7 9 24
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (13) (15) — —
’25 (19) (20) (15) (11) (66)
’24 (19) (15) (6) (19) (58)
’23 (31) (21) (23) (8) (84)
’22 (29) (24) 29 (22) (46)
’21 68 (31) (24) (24) (11)
’20 (26) (26) (22) (13) (87)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (12) (13) (15) — —
’25 (19) (20) (15) (12) (66)
’24 (19) (15) (6) (19) (59)
’23 (32) (22) (24) (8) (86)
’22 (30) (25) 28 (22) (49)
’21 67 (33) (25) (25) (17)
’20 (27) (28) (23) (15) (92)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Sep ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 7 6 11 22 24 116 25 49 69 34 45 +19.3% 13 9 21 (15.5%)
Gross margin, % 0.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 +100.0 pt
EBT (8) (21) (46) (93) (109) (31) (73) (43) 7 (47) (39) +21.2%
EBT margin, % (117.69) (325.45) (423.02) (417.65) (448.86) (26.49) (290.50) (87.28) 10.43 (136.03) 0.00 (18.3) pt
Net income (8) (21) (46) (93) (109) (31) (112) (61) 7 (46) (39) +21.0%
Per share, $
Per share, $ Revenue 0.14 12.24 20.72 15.90 14.02 59.12 8.57 12.69 10.05 2.67 0.00 +38.8%
Earnings (0.16) (39.84) (87.63) (66.37) (62.76) (15.62) (38.14) (15.96) 1.05 (3.56) (1.23) +41.2%
Cash flow 1.84 (45.63) (98.46) (50.79) (50.43) (5.55) (15.62) (21.90) (8.55) (5.13) (1.89) n/m
Capex 0.00 (10.41) (27.15) (17.64) (2.90) (2.97) (1.13) (0.57) (0.03) (0.05) (0.02) n/m
Free cash flow 1.84 (56.04) (125.62) (68.43) (53.34) (8.52) (16.75) (22.46) (8.58) (5.18) (1.91) n/m
Book value (0.09) (49.78) 76.07 98.92 25.64 46.65 20.63 4.91 8.25 7.19 1.89 n/m
Shares, m 50 1 1 1 2 2 3 4 7 13 23 (14.1%)
Valuation, ×
Valuation, × P/E 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1.97 0.00 0.00 0.2
P/S 25.26 25.26 25.26 26.20 17.85 3.76 4.10 0.88 0.38 1.56 6.54 13.0
P/B 6.88 6.88 6.88 4.21 9.76 4.76 1.70 2.26 0.46 0.58 5.70 4.4
EV/Sales 15.77 15.77 15.77 18.07 14.51 2.53 (2.57) (1.45) (0.55) (1.16) 5.22 7.7
EV/FCF (2.60) (2.60) (2.60) (4.20) (3.81) (18.40) 1.31 0.82 0.65 0.60 (4.49) (3.1)
Cash, $m
Cash, $m Operating cash flow 92 (24) (52) (71) (87) (11) (46) (84) (58) (66) (52) n/m
Capex (2) (6) (14) (25) (5) (6) (3) (2) 0 (1) (1) (12.3%)
Free cash flow 92 (30) (66) (96) (92) (17) (49) (86) (59) (66) (52) n/m
Balance, $m
Balance, $m Working capital 86 55 102 167 63 126 139 86 80 110 78 +2.7%
Net debt (93) (63) (103) (181) (81) (141) (167) (117) (64) (93) (59) 0.0%
Shareholders’ equity (5) (26) 40 138 44 91 60 19 56 92 52 n/m
Returns, %
Returns, % ROA (9.64) (24.67) (43.58) (49.69) (56.57) (16.92) (49.65) (30.82) 4.84 (31.45) (36.04) (21.8) pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE 53.02 135.60 (677.86) (104.20) (119.30) (45.14) (147.28) (154.66) 19.05 (61.52) (112.69) (114.5) pt
People
People Employees — — 127 199 184 45 198 109 108 68 — (8.5%)
Revenue/emp, $m 0.00 0.00 0.09 0.11 0.13 2.57 0.13 0.45 0.64 0.50 — n/m
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 5 Nov 2026

Precision BioSciences, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
PRLD Prelude Therapeutics Incorporated $283.7M — (loss-making) — (loss-making) +42.60% (above 0%: growing) n/m +40.32% (above 0%: growing) 100.00% (270.93%) Compare
FULC Fulcrum Therapeutics, Inc. $280.8M — (loss-making) — (loss-making) +27,018.64% (above 0%: growing) n/m −13.05% (below 0%: shrinking) 100.00% 0.00% Compare
OCGN Ocugen, Inc. $276.9M — (loss-making) — (loss-making) +11.36% (above 0%: growing) n/m −22.15% (below 0%: shrinking) 100.00% (909.94%) Compare
DTIL Precision BioSciences, Inc. $275.7M — (loss-making) — (loss-making) +37,272.41% (above 0%: growing) n/m −0.52% (below 0%: shrinking) 100.00% 0.00%
NAUT Nautilus Biotechnology, Inc. $273.9M — (loss-making) — — n/m −28.59% (below 0%: shrinking) 89.74% (7,152.56%) Compare
IPSC Century Therapeutics, Inc. $273.4M — (loss-making) — (loss-making) +12,667.72% (above 0%: growing) n/m +26.66% (above 0%: growing) 100.00% 0.00% Compare
TTRX Turn Therapeutics Inc. $273.0M — (loss-making) — — n/m −74.76% (below 0%: shrinking) — 0.00% Compare
VOGX Vogenx Inc $270.8M — — — n/m — — 0.00% Compare
SABS SAB Biotherapeutics, Inc. $267.5M — (loss-making) 19.9× −90.95% (below 0%: shrinking) n/m −59.75% (below 0%: shrinking) 100.00% 0.00% Compare
Median of peers $273.6M — — +42.60% — −22.15% 100.00% 0.00%

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 8 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 2.19m 2.26m 11.65
2024 4.31m 2.00m 10.67
2023 2.04m (206.56k) 30.67

Ownership

Directors and executive officers, together 2.70%
Octagon Capital Advisors 9.00%
Empery Asset Management 8.90%
Aberdeen Group 8.30%
Bleichroeder Holdings 7.40%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more. Read the proxy statement

Precision BioSciences, Inc. (DTIL) Latest News

5 Nov

Impact 4 · · Business Wire
Impact 3 · · Business Wire

3 Nov

Impact 3 · · Business Wire

29 Oct

Impact 3 · · Business Wire

8 Oct

Impact 3 · · Business Wire

24 Aug

Impact 4 ·

6 Aug

Impact 3 ·

21 May

Impact 3 · · Business Wire

14 May

Impact 4 ·

13 May

Impact 3 · · Simply Wall St.

5 May

Impact 4 · · Business Wire
Impact 3 · · Zacks

29 Apr

Impact 4 · · Business Wire

28 Apr

Impact 3 · · Business Wire

22 Apr

Impact 3 · · Business Wire

15 Apr

Impact 4 · · Business Wire

12 Mar

Impact 4 · · Zacks
Impact 4 · · Business Wire
Impact 3 · · Associated Press Finance

11 Mar

Impact 4 ·

10 Mar

Impact 3 · · Business Wire

9 Mar

Impact 4 · · Business Wire

8 Mar

Impact 4 · · Simply Wall St.
Impact 4 · · Simply Wall St.

2 Mar

Impact 4 · · Business Wire

11 Feb

Impact 4 · · Business Wire

12 Jan

Impact 4 · · Business Wire

19 Nov

Impact 4 · · Business WireClinical Trials ArenaGuruFocus.comMotley FoolClinical Trials ArenaGuruFocus.comMT NewswiresZacks

10 Nov

Impact 4 · · Business Wire
Impact 3 · · Business Wire
stockrow.com/DTIL · Data as of Nov 5, 2026 · For information only; not investment advice. · © 2026 stockrow.com